ID   PC-3 9-7-11
AC   CVCL_D3N6
SY   PSMA/PC-3; Clone 9-7-11
DR   Wikidata; Q127383017
RX   PubMed=24403448;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:3788; FOLH1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0035 ! PC-3
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   PubMed=24403448;
RA   Sugimoto Y., Hirota M., Yoshikawa K., Sumitomo M., Nakamura K.,
RA   Ueda R., Niwa R., Suzawa T., Yamasaki M., Shitara K., Kato T.,
RA   Nakamura K.;
RT   "The therapeutic potential of a novel PSMA antibody and its IL-2
RT   conjugate in prostate cancer.";
RL   Anticancer Res. 34:89-97(2014).
//